Skip to main content
Erschienen in: Diabetes Therapy 8/2020

Open Access 26.06.2020 | Original Research

Cardiovascular Outcomes Post Percutaneous Coronary Intervention in Patients with Obstructive Sleep Apnea and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

verfasst von: Hong Wang, Xinxin Li, Zhangui Tang, Guoping Gong

Erschienen in: Diabetes Therapy | Ausgabe 8/2020

Abstract

Introduction

Type 2 diabetes mellitus (T2DM) is a major risk factor for the occurrence of cardiovascular diseases. Similar to T2DM, obstructive sleep apnea (OSA) is also known to be a risk factor for cardiovascular diseases. In this analysis, we aimed to systematically compare the post-interventional cardiovascular outcomes observed in patients with T2DM with versus without OSA.

Methods

Electronic databases were searched for relevant publications comparing the cardiovascular outcomes following percutaneous coronary intervention (PCI) in patients with T2DM with OSA. Cardiovascular outcomes were considered as the relevant endpoints. The RevMan software 5.3 was used to carry out the statistical analysis. Odds ratios (OR) with 95% confidence intervals (CI) were used to represent the results following data assessment.

Results

A total of 1168 participants with T2DM were included in this analysis, of whom 614 had co-existing OSA. The time period of patients’ enrollment varied from year 2002 to 2017. Our current analysis showed that major adverse cardiac events (MACEs) (OR 2.28, 95% CI 1.24–4.18; P = 0.008) and all-cause mortality (OR 1.95, 95% CI 1.08–3.54; P = 0.03) were significantly higher in the OSA subgroup. However, major adverse cerebrovascular and cardiovascular (MACCEs) (OR 1.38, 95% CI 0.97–1.98; P = 0.07) and cardiac death (OR 1.79, 95% CI 0.77–4.16; P = 0.18) were not significantly different post PCI. In addition, hospitalization for heart failure (OR 1.99, 95% CI 0.43–9.25; P = 0.38), re-infarction (OR 1.52, 95% CI 0.85–2.70; P = 0.16), stroke (OR 1.81, 95% CI 0.81–4.08; P = 0.15), target vessel revascularization (TVR) (OR 1.54, 95% CI 0.98–2.42; P = 0.06), and target lesion revascularization (TLR) (OR 1.32, 95% CI 0.80–2.18; P = 0.28) were also not significantly different post PCI in the patients with T2DM with versus without OSA.

Conclusion

OSA was associated with a significant increase in all-cause mortality and MACEs post PCI in these patients with T2DM. Therefore, special care and continuous follow-up might be required for patients with T2DM with associated OSA after PCI. However, as a result of the limited number of participants, further larger studies would be required to confirm these hypotheses.
Hinweise

Digital Features

To view digital features for this article go to https://​doi.​org/​10.​6084/​m9.​figshare.​12505346.
Key Summary Points
Why carry out this study?
Similar to diabetes mellitus, obstructive sleep apnea (OSA) is also known to be a risk factor for cardiovascular diseases.
However, no study has yet systematically assessed the cardiovascular outcomes in patients with co-existing diabetes mellitus and OSA following coronary angioplasty.
What was learned from the study?
OSA was associated with a significant increase in all-cause mortality and major adverse cardiac events post coronary intervention in these patients with diabetes mellitus.
Therefore, special care and continuous follow-up might be required for patients with diabetes mellitus with associated OSA following percutaneous coronary intervention.

Introduction

It is well known that type 2 diabetes mellitus (T2DM) is a major risk factor for the occurrence of cardiovascular diseases [1]. Similar to T2DM, obstructive sleep apnea (OSA) [2], characterized by recurrent partial or complete upper airway obstruction causing hypoxia and arousal from sleep, is also known to be a risk factor for cardiovascular diseases [3]. Several studies have already shown T2DM to be associated with worse cardiovascular outcomes following percutaneous coronary intervention (PCI) [4]. Recent studies have also shown that in those patients with acute coronary syndrome (ACS), OSA is associated with a higher risk of short- and long-term cardiovascular events compared to those patients without OSA [5]. However, no study has yet systematically assessed the cardiovascular outcomes in patients with co-existing T2DM and OSA following coronary angioplasty. In this analysis, we aimed to systematically compare the post-interventional cardiovascular outcomes observed in patients with T2DM with versus without OSA.

Methods

Data Sources

The following search databases were explored for relevant publications:

Searched Terms and Search Strategies

The aforementioned databases were searched for relevant publications comparing the cardiovascular outcomes in patients with T2DM with versus without OSA following PCI by using the following search terms:
  • Obstructive sleep apnea, diabetes mellitus, percutaneous coronary intervention
  • Obstructive sleep apnea and percutaneous coronary intervention
  • Obstructive sleep apnea, type 2 diabetes mellitus, percutaneous coronary intervention
  • Obstructive sleep apnea, diabetes mellitus, coronary angioplasty
  • Obstructive sleep apnea, diabetes mellitus, coronary revascularization
  • Obstructive sleep apnea, coronary angioplasty
  • Obstructive sleep apnea, diabetes mellitus, PCI
Only studies published in English language were considered relevant to this research.

Inclusion and Exclusion Criteria

Criteria for inclusion were:
  • Patients with T2DM with OSA who have undergone PCI.
  • Post-PCI cardiovascular outcomes were reported.
  • English publications.
Criteria for exclusion:
  • Patients with T2DM without OSA.
  • Post-interventional cardiovascular outcomes were not reported.
  • Repeated studies.
  • Non-English publications.
  • Literature reviews, meta-analyses and systematic reviews as well as case studies.

Outcomes

The outcomes assessed in this analysis were:
  • Major adverse cerebrovascular and cardiac events (MACCEs), defined as the total number of deaths, re-infarction, revascularization, and stroke
  • Major adverse cardiac events (MACEs), defined as the total number of deaths, re-infarction, and revascularization
  • Cardiac death
  • All-cause mortality
  • Re-infarction
  • Stroke
  • Target vessel revascularization (TVR)
  • Target lesion revascularization (TLR)
  • Hospitalization for heart failure.
All patients were revascularized by PCI. The outcomes reported in the original studies are listed in Table 1.
Table 1
Outcomes reported in these patients with type 2 diabetes mellitus
Studies
Outcomes reported
Approximate mean follow-up time period
Treatment strategy
Fan [8]
MACCE, cardiovascular death, MI, stroke, hospitalization for unstable angina, hospitalization for heart failure, all-cause mortality, TVR, TLR
1 year
PCI or CABG
Lee [9]
Death, re-infarction, stroke, TVR, admission due to heart failure, major adverse events
18 months
PCI
Lee [10]
MI, stroke, revascularization, stent thrombosis, MACCE, cardiovascular death, all-cause mortality
1.9 years
PCI
Loo [11]
MI, revascularization, stroke, hospitalization for heart failure, cardiac death, MACCE
24 months
PCI
Meng [12]
MACEs, cardiac death, heart failure, TVR, stroke
1 year
PCI
Nakashima [13]
TVR, re-infarction, MACEs
4 years
PCI
Wu [14]
Revascularization, TLR, TVR, MI, stroke, death, MACE, MACCE
1 and 5 years
PCI
Yumino [15]
TVR, cardiac death, MACEs
8 months
PCI
MACCEs major adverse cardiovascular and cerebrovascular events, MACEs major adverse cardiac events, MI myocardial infarction, TVR target vessel revascularization, TLR target lesion revascularization, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting
The mean follow-up time period ranged between 1 and 5 years.

Data Extraction and Quality Assessment

Data were extracted by four independent authors. First of all the first authors’ names, the publication year, the total number of participants with T2DM, the total number of participants with T2DM with versus without OSA, the baseline characteristics including the mean age of the participants, the percentage of male patients, the percentage of participants with T2DM who were current smokers, who had hypertension, and those who had dyslipidemia were all carefully extracted. In addition, the type of study, the type of revascularization procedures, the time period of patients’ enrollment, the cardiovascular outcomes reported in the original studies, and the corresponding follow-up time period were all carefully extracted.
If any of the authors disagreed about the inclusion of certain data or had any difficulty in the data extraction process, the issues were carefully discussed among all the authors, and then a final decision was made by the corresponding author.
The methodological quality of the studies was assessed by the Newcastle Ottawa Scale (NOS) [6]. Grades were allotted to the studies to denote low (A), moderate (B), or high risk (C) of bias.

Statistical Analysis

The RevMan software 5.3 was used to carry out the statistical analysis. Odds ratios (OR) with 95% confidence intervals (CI) were used to represent the results following data assessment. There were two ways to assess heterogeneity: (1) using the Q statistic test whereby a P value less than or equal to 0.05 was considered statistically significant; (2) the I2 test whereby heterogeneity was increased with an increasing I2 value. An I2 value with a low percentage denoted low heterogeneity whereas an I2 value with a high percentage denoted increased heterogeneity.
A fixed statistical effect was used during data analysis if the heterogeneity was low; however, a random statistical effect model was used in case of high heterogeneity.
Sensitivity analysis was also carried out to prove that the main results were not influenced by any of the studies. In addition, a funnel plot was generated to visually assess publication bias.

Compliance with Ethical Guidelines

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Results

Search Outcomes

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guideline was followed [7]. A thorough search through the electronic databases resulted in a total of 1080 publications. After an assessment of the titles and abstracts by the authors, 988 publications were eliminated and the remaining 92 full-text publications were assessed for eligibility.
Full-text articles were eliminated on the basis of the following criteria:
  • Involved participants did not undergo PCI (n = 7).
  • Post-interventional outcomes were not reported (n = 3).
  • Non-English publications (n = 4).
  • Case studies (n = 6).
  • Literature review (n = 1).
  • Systematic reviews and meta-analyses (n = 3).
  • Repeated studies (n = 60).
Finally only eight studies [815] were included in this analysis as shown in Fig. 1.

Main and Baseline Features

Table 2 shows the main characteristics of the studies included in this analysis. The time period of patients’ enrollment varied from year 2002 to 2017. A total of 1168 participants with T2DM were included in this analysis, of whom 614 had co-existing OSA.
Table 2
Main features of the studies
Studies
Type of study
Year of participants’ enrollment
No. of patients with T2DM with OSA (n)
No. of patients with T2DM without OSA (n)
NOS grade
Fan [8]
Prospective
2015–2017
121
127
B
Lee [9]
Prospective
2007–2008
21
21
B
Lee [10]
Prospective
2011–2014
271
284
B
Loo [11]
Prospective
2011–2012
9
8
B
Meng [12]
OS
2008
19
11
B
Nakashima [13]
OS
2003–2009
45
51
B
Wu [14]
Retrospective
2002–2012
100
33
B
Yumino [15]
OS
 
28
19
B
Total no. of participants with T2DM (n)
  
614
554
 
OS observational study, T2DM type 2 diabetes mellitus, OSA obstructive sleep apnea, NOS Newcastle Ottawa Scale
On the basis of the assessment by the NOS, a grade B was allotted to the studies indicating a moderate risk of bias as shown in Table 2.
The baseline features of the studies are listed in Table 3. According to the baseline features listed, the mean age of the participants ranged between 50.9 and 71.0 years. The majority of these patients with T2DM were male participants with an average percentage ranging from 66.7% to 98.4%. The mean percentages of participants with hypertension (49.2% to 79.2%), dyslipidemia (25.7% to 88.6%), and current smoker (16.7% to 63.6%) are also given in Table 3.
Table 3
Baseline features of the participants with T2DM with versus without OSA
Studies
Age (years)
Male (%)
HBP (%)
DYS (%)
CS (%)
DM (%)
OSA/NOSA
OSA/NOSA
OSA/NOSA
OSA/NOSA
OSA/NOSA
OSA/NOSA
Fan [8]
57.7/57.2
84.9/80.3
68.2/63.6
26.6/25.7
50.1/50.9
100/100
Lee [9]
55.2/50.9
97.7/98.4
56.8/49.2
88.6/80.3
54.6/60.7
100/100
Lee [10]
59.0/57.5
88.1/82.9
68.0/54.0
60.1/58.7
35.4/35.6
100/100
Loo [11]
56.7/52.8
75.0/93.2
66.7/38.6
87.5/70.5
16.7/63.6
100/100
Meng [12]
66.5/66.8
70.7/66.7
75.7/79.2
68.9/66.7
36.5/31.3
100/100
Nakashima [13]
71.0/65.0
77.0/73.0
63.0/56.0
56.0/55.0
32.0/45.0
100/100
Wu [14]
55.0/55.0
84.2/83.2
73.8/70.5
44.6/40.0
24.6/23.2
100/100
Yumino [15]
66.0/65.0
84.0/68.0
78.0/79.0
84.0/53.0
63.0/58.0
100/100
HBP high blood pressure, DYS dyslipidemia, CS current smoker, DM diabetes mellitus, OSA obstructive sleep apnea, NOSA non-obstructive sleep apnea

Results of this Analysis

All patients with T2DM with or without OSA who underwent PCI were included. Our current analysis showed that MACEs (OR 2.28, 95% CI 1.24–4.18; P = 0.008) and all-cause mortality (OR 1.95, 95% CI 1.08–3.54; P = 0.03) were significantly higher in the OSA subgroup as shown in Fig. 2. However, MACCEs (OR 1.38, 95% CI 0.97–1.98; P = 0.07) and cardiac death (OR 1.79, 95% CI 0.77–4.16; P = 0.18) were not significantly different post PCI between these two subgroups of patients with T2DM with versus without OSA as shown in Fig. 2.
In addition, hospitalization for heart failure (OR 1.99, 95% CI 0.43–9.25; P = 0.38), re-infarction (OR 1.52, 95% CI 0.85–2.70; P = 0.16), stroke (OR 1.81, 95% CI 0.81–4.08; P = 0.15), TVR (OR 1.54, 95% CI 0.98–2.42; P = 0.06) and TLR (OR 1.32, 95% CI 0.80–2.18; P = 0.28) were also not significantly different post PCI as shown in Fig. 3.
Sensitivity analysis was carried out by an exclusion method whereby each study was excluded one by one and a new analysis was carried out each time and the new results were compared for any significant change compared to the main result of this analysis. However, consistent results were obtained throughout.
The funnel plot (Fig. 4) showed that there was no evidence of publication bias among the studies that were included to assess these cardiovascular outcomes post PCI in these patients with T2DM with versus without OSA.
A summary of the results is shown in Table 4.
Table 4
Results of this analysis
Outcomes
OR with 95% CI
P value
I2 value (%)
Major adverse cardiovascular and cerebrovascular events (MACCEs)
1.38 [0.97–1.98]
0.07
0
Major adverse cardiac events (MACEs)
2.28 [1.24–4.18]
0.008
0
Cardiac death
1.79 [0.77–4.16]
0.18
0
All-cause mortality
1.95 [1.08–3.54]
0.03
0
Hospitalization for heart failure
1.99 [0.43–9.25]
0.38
0
Re-infarction
1.52 [0.85–2.70]
0.16
0
Stroke
1.81 [0.81–4.08]
0.15
0
Target vessel revascularization (TVR)
1.54 [0.98–2.42]
0.06
0
Target lesion revascularization (TLR)
1.32 [0.80–2.18]
0.28
0
OR odds ratios, CI confidence intervals

Discussion

In a systematic review and meta-analysis which was published in 2012, the authors concluded that even though OSA appeared to be associated with stroke, the relationship between OSA and acute coronary syndrome or cardiovascular mortality would require further research [16]. This current analysis focused on the post-interventional cardiovascular outcomes observed in patients with T2DM with versus without OSA.
Our results from this analysis have shown that in patients with T2DM, OSA was associated with a significantly higher all-cause mortality and MACEs following coronary angioplasty. However, the results for re-infarction, repeated revascularization, cardiac death, MACCEs, stroke, and re-hospitalization for heart failure were not significant.
The fact that MACEs were significantly higher in patients with T2DM and co-existing OSA whereas MACCEs were not significantly different following PCI might be explained by the all-cause mortality being significantly higher, thereby contributing to significantly higher MACEs whereas stroke was not significantly different between these two groups, rendering MACCEs non-significant.
OSA has been linked to cardiovascular events by several mechanisms [17]. Studies have shown repeated cycles of intermittent hypoxemia, sympathetic activation, and sleep disruption as a result of OSA could lead to several vascular abnormalities such as endothelial dysfunction, vascular inflammation, and high platelet reactions [18].
Similar to the results of this current study, another recently published meta-analysis based on the association of OSA with cardiovascular outcomes after PCI showed a significantly higher risk of MACEs and all-cause mortality associated with this intermittent hypoxemic disease [19]. The authors concluded that patients with OSA had a greater risk of subsequent cardiovascular outcomes after PCI. They also stated that whether prevention of OSA might improve cardiovascular outcomes should further be investigated. A recent meta-analysis of prospective studies additionally showed that OSA apparently increased the risk of cardiac death, repeated revascularization, and non-fatal myocardial infarction after PCI [20]. Nevertheless, the study dealt with the general population with coronary artery disease whereas our current paper was based on patients with T2DM with coronary artery disease.
In another study aimed at showing the clinical significance of OSA in patients with ACS in relation to diabetes status, OSA was associated with a higher risk of MACCEs at 1-year follow-up, following ACS in these patients with diabetes mellitus, but with different results in patients without diabetes mellitus [21]. The study also showed that longer hypoxia in these patients with diabetes mellitus and OSA could further increase the risk of MACCEs to 31%. Similarly, among 168 consecutive patients who were admitted with unstable angina or non-ST elevation ACS, the authors suggested that OSA might represent an aggravating factor for such patients [22].

Limitations

This study has several limitations. Firstly, the total number of participants was small and this might have had an impact on the results and conclusion. Secondly, a few important cardiovascular outcomes including stent thrombosis were not assessed since they were not reported in the original studies, or were reported in only one study whereby a comparison was not possible. In addition, since the participants were on anticoagulants, bleeding outcomes would have also been interesting, but these outcomes were not reported in the original studies and therefore could not be analyzed in our paper. Another limitation could be the inclusion of data which were extracted from observational studies and could have contributed to the introduction of bias.

Conclusion

OSA was associated with a significant increase in all-cause mortality and MACEs post PCI in these patients with T2DM. Therefore, special care and continuous follow-up might be required for patients with T2DM with associated OSA following PCI. As a result of the limited number of participants, further larger studies would be required to confirm these hypotheses.

Acknowledgements

Funding

No external funding or sponsorship was received for the publication of this article. This work was supported by Guangxi Medical and Health Appropriate Technology Development and Promotion Application Project (S2017077) and the Guangxi Nanning Qingxiu District Science and Technology Development Project (Grant No. 2014S06).

Authorship

All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Authorship Contributions

Hong Wang, Xinxin Li, Zhangui Tang, and Guoping Gong were responsible for the conception and design, acquisition of data, analysis and interpretation of data, drafting the initial manuscript and revising it critically for important intellectual content. Hong Wang, Xinxin Li, Zhangui Tang, and Guoping Gong approved the final manuscript as it is.

Disclosures

The authors Dr Hong Wang, Dr Xinxin Li, Dr Zhangui Tang, and Dr Guoping Gong declare that they have no competing interests.

Compliance with Ethics Guidelines

This meta-analysis is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Data Availability

All data generated or analyzed during this study are included in this published article. References of the original papers involving the data source which have been used in this paper have been listed in the main text of this current manuscript. All data are publicly available in electronic databases.

Open Access

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by-nc/​4.​0/​.
Literatur
1.
Zurück zum Zitat Wang CCL, Hess CN, Hiatt WR, Goldfine AB. Atherosclerotic cardiovascular disease and heart failure in type 2 diabetes—mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459–502.CrossRef Wang CCL, Hess CN, Hiatt WR, Goldfine AB. Atherosclerotic cardiovascular disease and heart failure in type 2 diabetes—mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459–502.CrossRef
3.
Zurück zum Zitat Mazzotti DR, Keenan BT, Lim DC, Gottlieb DJ, Kim J, Pack AI. Symptom subtypes of obstructive sleep apnea predict incidence of cardiovascular outcomes. Am J Respir Crit Care Med. 2019;200(4):493–506.PubMedPubMedCentralCrossRef Mazzotti DR, Keenan BT, Lim DC, Gottlieb DJ, Kim J, Pack AI. Symptom subtypes of obstructive sleep apnea predict incidence of cardiovascular outcomes. Am J Respir Crit Care Med. 2019;200(4):493–506.PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Bundhun PK, Zi Jia W, Chen M-H. Impact of modifiable cardiovascular risk factors on mortality after percutaneous coronary intervention: a systematic review and meta-analysis of 100 studies. Medicine (Baltimore). 2015;94(50):e2313.CrossRef Bundhun PK, Zi Jia W, Chen M-H. Impact of modifiable cardiovascular risk factors on mortality after percutaneous coronary intervention: a systematic review and meta-analysis of 100 studies. Medicine (Baltimore). 2015;94(50):e2313.CrossRef
5.
Zurück zum Zitat Maeder MT, Schoch OD, Rickli H. A clinical approach to obstructive sleep apnea as a risk factor for cardiovascular disease. Vasc Health Risk Manag. 2016;12:85–103.PubMedPubMedCentralCrossRef Maeder MT, Schoch OD, Rickli H. A clinical approach to obstructive sleep apnea as a risk factor for cardiovascular disease. Vasc Health Risk Manag. 2016;12:85–103.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef
7.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;21(339):b2700.CrossRef Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;21(339):b2700.CrossRef
8.
Zurück zum Zitat Fan J, Wang X, Ma X, Somers VK, Nie S, Wei Y. Association of obstructive sleep apnea with cardiovascular outcomes in patients with acute coronary syndrome. J Am Heart Assoc. 2019;8(2):e010826.PubMedPubMedCentralCrossRef Fan J, Wang X, Ma X, Somers VK, Nie S, Wei Y. Association of obstructive sleep apnea with cardiovascular outcomes in patients with acute coronary syndrome. J Am Heart Assoc. 2019;8(2):e010826.PubMedPubMedCentralCrossRef
9.
10.
Zurück zum Zitat Lee C-H, Sethi R, Li R, et al. Obstructive sleep apnea and cardiovascular events after percutaneous coronary intervention. Circulation. 2016;133(21):2008–177.PubMedCrossRef Lee C-H, Sethi R, Li R, et al. Obstructive sleep apnea and cardiovascular events after percutaneous coronary intervention. Circulation. 2016;133(21):2008–177.PubMedCrossRef
11.
Zurück zum Zitat Loo G, Tan AY, Koo C-Y. Prognostic implication of obstructive sleep apnea diagnosed by post-discharge sleep study in patients presenting with acute coronary syndrome. Sleep Med. 2014;15(6):631–6.PubMedCrossRef Loo G, Tan AY, Koo C-Y. Prognostic implication of obstructive sleep apnea diagnosed by post-discharge sleep study in patients presenting with acute coronary syndrome. Sleep Med. 2014;15(6):631–6.PubMedCrossRef
12.
Zurück zum Zitat Meng S, Fang L, Wang C-Q, et al. Impact of obstructive sleep apnoea on clinical characteristics and outcomes in patients with acute coronary syndrome following percutaneous coronary intervention. J Int Med Res. 2009;37(5):1343–53.PubMedCrossRef Meng S, Fang L, Wang C-Q, et al. Impact of obstructive sleep apnoea on clinical characteristics and outcomes in patients with acute coronary syndrome following percutaneous coronary intervention. J Int Med Res. 2009;37(5):1343–53.PubMedCrossRef
13.
Zurück zum Zitat Nakashima H, Kurobe M, Minami K, et al. Effects of moderate-to-severe obstructive sleep apnea on the clinical manifestations of plaque vulnerability and the progression of coronary atherosclerosis in patients with acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2015;4(1):75–84.PubMedCrossRef Nakashima H, Kurobe M, Minami K, et al. Effects of moderate-to-severe obstructive sleep apnea on the clinical manifestations of plaque vulnerability and the progression of coronary atherosclerosis in patients with acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2015;4(1):75–84.PubMedCrossRef
14.
Zurück zum Zitat Xiaofan Wu, Lv S, Xiaohong Yu, Yao L, Mokhlesi B, Wei Y. Treatment of OSA reduces the risk of repeat revascularization after percutaneous coronary intervention. Chest. 2015;147(3):708–18.CrossRef Xiaofan Wu, Lv S, Xiaohong Yu, Yao L, Mokhlesi B, Wei Y. Treatment of OSA reduces the risk of repeat revascularization after percutaneous coronary intervention. Chest. 2015;147(3):708–18.CrossRef
15.
Zurück zum Zitat Yumino D, Tsurumi Y, Takagi A, et al. Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. Am J Cardiol. 2007;99:26–30.PubMedCrossRef Yumino D, Tsurumi Y, Takagi A, et al. Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. Am J Cardiol. 2007;99:26–30.PubMedCrossRef
16.
Zurück zum Zitat Loke YK, William J, Brown L, Kwok CS, Niruban A, Myint PK. Association of obstructive sleep apnea with risk of serious cardiovascular events: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012;5(5):720–8.PubMedCrossRef Loke YK, William J, Brown L, Kwok CS, Niruban A, Myint PK. Association of obstructive sleep apnea with risk of serious cardiovascular events: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012;5(5):720–8.PubMedCrossRef
17.
Zurück zum Zitat Rahangdale S, Yeh SY, Novack V, et al. The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea. J Clin Sleep Med. 2011;7:172–8.PubMedPubMedCentralCrossRef Rahangdale S, Yeh SY, Novack V, et al. The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea. J Clin Sleep Med. 2011;7:172–8.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Wang X, Fan J-Y, Zhang Y, Nie S-P, Wei Y-X. Association of obstructive sleep apnea with cardiovascular outcomes after percutaneous coronary intervention: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(17):e0621.CrossRef Wang X, Fan J-Y, Zhang Y, Nie S-P, Wei Y-X. Association of obstructive sleep apnea with cardiovascular outcomes after percutaneous coronary intervention: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(17):e0621.CrossRef
20.
Zurück zum Zitat Hua Qu, Guo M, Zhang Y, Shi D-Z. Obstructive sleep apnea increases the risk of cardiac events after percutaneous coronary intervention: a meta-analysis of prospective cohort studies. Sleep Breath. 2018;22(1):33–40.CrossRef Hua Qu, Guo M, Zhang Y, Shi D-Z. Obstructive sleep apnea increases the risk of cardiac events after percutaneous coronary intervention: a meta-analysis of prospective cohort studies. Sleep Breath. 2018;22(1):33–40.CrossRef
21.
Zurück zum Zitat Wang X, Fan J, Yunhui Du, et al. Clinical significance of obstructive sleep apnea in patients with acute coronary syndrome in relation to diabetes status. BMJ Open Diabetes Res Care. 2019;7(1):e000737.PubMedPubMedCentralCrossRef Wang X, Fan J, Yunhui Du, et al. Clinical significance of obstructive sleep apnea in patients with acute coronary syndrome in relation to diabetes status. BMJ Open Diabetes Res Care. 2019;7(1):e000737.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Correia LCL, Souza AC, et al. Obstructive sleep apnea affects hospital outcomes of patients with non-ST-elevation acute coronary syndromes. Sleep. 2012;35(9):1241–5.PubMedPubMedCentralCrossRef Correia LCL, Souza AC, et al. Obstructive sleep apnea affects hospital outcomes of patients with non-ST-elevation acute coronary syndromes. Sleep. 2012;35(9):1241–5.PubMedPubMedCentralCrossRef
Metadaten
Titel
Cardiovascular Outcomes Post Percutaneous Coronary Intervention in Patients with Obstructive Sleep Apnea and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
verfasst von
Hong Wang
Xinxin Li
Zhangui Tang
Guoping Gong
Publikationsdatum
26.06.2020
Verlag
Springer Healthcare
Erschienen in
Diabetes Therapy / Ausgabe 8/2020
Print ISSN: 1869-6953
Elektronische ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-020-00870-6

Weitere Artikel der Ausgabe 8/2020

Diabetes Therapy 8/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.